Elevated Myostatin Levels in Patients with Liver Disease: A Potential Contributor to Skeletal Muscle Wasting
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Loss of skeletal muscle mass is a poorly understood complication of end-stage liver disease (ESLD). Based on recent stem cell literature, we hypothesized that the potent negative regulator of muscle mass, myostatin, could play a role in the muscle loss associated with ESLD. In this preliminary investigation, we measured myostatin levels in patients undergoing liver transplant evaluation, using a novel enzyme-linked immunosensitivity assay. Myostatin levels were significantly elevated in patients with ESLD compared with healthy controls. These data suggest that myostatin deserves further investigation as a target for therapies designed to preserve muscle mass in patients with ESLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481 · cited 1×
“Because of the potency of myostatin in causing muscle loss, several therapeutic candidates are in development to block the effects of myostatin in various chronic diseases.(10,11) Given the benefit of antimyostatin strategies in preclinical models, our study suggests that antimyostatin therapies deserve further explor…”
Myostatin Inhibits IGF-I-Induced Myotube Hypertrophy through Akt
Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A., & Rosenzweig, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00043.2009 · Cited by 231
Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils
Tessari, P. (2003) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200301000-00012 · Cited by 93 · cited 1×
“Muscle loss secondary to liver disease is the result of increased muscle protein breakdown and decreased liver and muscle protein synthesis.(7) Liver disease is characterized by global hormonal dysregulation because most hormones are metabolized in liver; muscle loss in this setting is attributed to hormonal disruptio…”
Cited by
Nishikawa, H., Shiraki, M., Hiramatsu, A., Moriya, K., Hino, K., & Nishiguchi, S. (2016) · Hepatology Research · doi:10.1111/hepr.12774 · Cited by 656
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Sinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13549 · Cited by 316
Sarcopenia in cirrhosis: from pathogenesis to interventions
Ebadi, M., Bhanji, R. A., Mazurak, V. C., & Montano-Loza, A. J. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01605-6 · Cited by 292
Qiu, J., Thapaliya, S., Runkana, A., Yang, Y., Tsien, C., Mohan, M. L., Narayanan, A., Eghtesad, B., Mozdziak, P. E., McDonald, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317049110 · Cited by 292
Metadata
- Authors
- García, P. S., Cabbabe, A., Kambadur, R., Nicholas, G., & Csete, M.
- Venue
- Anesthesia & Analgesia
- Published
- 2010-09
- Volume
- 111
- Issue
- 3
- Pages
- 707-709
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2118479919
- Cited by
- 107
- References
- 4
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.